A novel calcipotriol and betamethasone dipropionate (CAL/BDP) PAD-cream demonstrates greater improvements in daily activities and personal relationships than CAL/BDP gel/TS: a post-hoc analysis of DLQI outcomes from two phase 3 placebo-controlled randomized clinical trials in mild-to-moderate psoriasis.
Bruno HaliouaG CailletCharles TaïebA BewleyA Snel-PrentøM PraestegaardA ArmstrongAndreas PinterPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2023)